Agios Pharmaceuticals elects Jay Backstrom, M.D., MPH to board

AGIOS PHARMACEUTICALS, INC.

Dr. Backstrom appointed as Class III director, term until 2028 Annual Meeting.
Appointed to Science and Technology Committee of the Board effective July 8, 2025.
Initial compensation includes stock option with $472,500 Black-Scholes value and RSUs valued at $157,500.
Annual cash compensation: $50,000 for board service plus $7,500 for committee service, quarterly pro-rata.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.